# Ruth J. Pepper

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ruth-j-pepper/

## Facts

| Field | Value |
| --- | --- |
| Citations | 2,452 |
| Field | Vasculitis and related conditions |
| h-index | 27 |
| i10-index | 37 |
| OpenAlex ID | https://openalex.org/A5111821057 |
| Works | 81 |

## Researcher papers

- [Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids](https://scholariq.org/papers/prospective-observational-single-centre-cohort-study-to-evaluate-the/)
- [The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis](https://scholariq.org/papers/the-genetic-architecture-of-membranous-nephropathy-and-its-potential-to-improve/)
- [Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids](https://scholariq.org/papers/rituximab-is-an-effective-treatment-for-lupus-nephritis-and-allows-a-reduction/)
- [Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production](https://scholariq.org/papers/rituximab-is-effective-in-the-treatment-of-refractory-churg-strauss-syndrome-and/)
- [Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis](https://scholariq.org/papers/leukocyte-and-serum-s100a8-s100a9-expression-reflects-disease-activity-in-anca/)
- [A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody–associated vasculitis](https://scholariq.org/papers/a-novel-glucocorticoid-free-maintenance-regimen-for-anti-neutrophil-cytoplasm/)
- [Rituximab in Membranous Nephropathy](https://scholariq.org/papers/rituximab-in-membranous-nephropathy/)
- [Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3–Antineutrophil Cytoplasmic Antibody–Associated Vasculitis](https://scholariq.org/papers/association-of-serum-calprotectin-s100a8-a9-level-with-disease-relapse-in/)
- [Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?](https://scholariq.org/papers/rituximab-in-adult-minimal-change-disease-and-focal-segmental-glomerulosclerosis/)
- [A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody–associated vasculitis](https://scholariq.org/papers/a-novel-glucocorticoid-free-maintenance-regimen-for-anti-neutrophil-cytoplasm-2/)
- [Outcomes of membranous and proliferative lupus nephritis – analysis of a single-centre cohort with more than 30 years of follow-up](https://scholariq.org/papers/outcomes-of-membranous-and-proliferative-lupus-nephritis-analysis-of-a-single/)

## Researcher topics

- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Systemic Sclerosis and Related Diseases](https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/)
- [Inflammasome and immune disorders](https://scholariq.org/topics/inflammasome-and-immune-disorders/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.